Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-342

Thanks RL,

All the best to you also & thanks again for your input here. I think they were waiting on results from both trials to do secondary analysis.

I also think that possibly SGLT2 drugs thrown into the mix may have had something to do with results, as this was a bit of a common theme throughout the presentation. Nina also said there was no fundamental reason that DMX-200 could not be prescribed with SGLT2 drugs & ARB for an additive effect & Professor Roger also discussed this as well. This will be interesting & if DMX-200 is showing an additive effect on top of SOC ARB + SGLT2, with no adverse drug interactions, this could be very commercially attractive to Big Pharmas all vying for the lion share of the CKD/DKD market.

Is it possible that DMX-200 has had a longer lasting effect once odd treatment, dampening down inflammation in the kidneys for patients who weren’t as sick, and therefore changed the course of the disease as Prof Packham discussed this possibility resulting in legacy effect on placebo in these 14 patients with <500mg/g baseline & which patients were on SGLT2 & which treatment cohorts? Many questions in my head, but guess we will find out soon enough.